THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 and is headquartered in Lyon, France.
Frequently asked questions
What sector does Theranexus SA (ALTHX) operate in?
Theranexus SA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Theranexus SA (ALTHX) current stock price?
As of the latest data, Theranexus SA stock price is €4.03, with a previous close of €4.25. Theranexus SA lost -€0.22 in the last trading session, representing a -5.06% loss.
What is Theranexus SA (ALTHX) current market capitalization?
Theranexus SA market cap is approximately 58.20 million.
What is Theranexus SA (ALTHX) Earnings Per Share (EPS)?
The trailing EPS is -€0.22.
Does Theranexus SA (ALTHX) pay dividends?
No. Theranexus SA does not pay a dividend.
What is Theranexus SA (ALTHX) beta (volatility) score?
Theranexus SA has a beta of 1.518, suggesting it is more volatile than the market.